Details for New Drug Application (NDA): 020778

✉ Email this page to a colleague

NDA 020778 describes VIRACEPT, which is a drug marketed by Agouron Pharms and is included in three NDAs. It is available from one supplier. Additional details are available on the VIRACEPT profile page.

The generic ingredient in VIRACEPT is nelfinavir mesylate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nelfinavir mesylate profile page.

Summary for 020778

Tradename:	VIRACEPT
Applicant:	Agouron Pharms
Ingredient:	nelfinavir mesylate
Patents:	0

Medical Subject Heading (MeSH) Categories for 020778

HIV Protease Inhibitors

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	POWDER;ORAL			Strength	EQ 50MG BASE/SCOOPFUL
Approval Date:	Mar 14, 1997	TE:		RLD:	No

Expired US Patents for NDA 020778

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997	5,484,926*PED	⤷ Subscribe
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997	6,162,812*PED	⤷ Subscribe
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997	5,952,343*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.